Chen DY, et al. - The published data on dosing down and then discontinuing biologic therapy in rheumatoid arthritis was studied by researchers, in order to determine the criteria for such dosing and the impact on clinical outcomes. As per the data from the published studies, down-titration and discontinuation of biologic disease modifying antirheumatic drug therapy may be attempted, with careful monitoring, in patients who have achieved low disease activity or remission. However, flare is likely, but cannot be predicted, in some patients.